Samsung Biologics, double-digit performance growth in the first quarter of 2026... the steady growth momentum continues

Samsung Biologics continued to deliver double-digit revenue and profit growth in the first quarter of 2026, with a clearly improved performance trend. According to its released preliminary results, operating profit on a consolidated basis was 5,808 billion KRW, up 35% from the same period last year; revenue was 12.571 trillion KRW, up 25.8%.

Net profit also reached 4,692 billion KRW, up 41.6%, with overall profitability improving in step. With revenue growth, the profit increase was even larger, indicating that the earnings structure—production efficiency and the high value-added contract manufacturing business of biopharmaceuticals—may have had a positive impact on performance. Biopharmaceutical contract manufacturing refers to taking on drug production business for global pharmaceutical companies; large orders and stable equipment operation are the core variables.

This time’s operating profit was broadly in line with the market consensus of 5,812 billion KRW compiled by Infomax, a financial information company. With no significant difference from market expectations, it means the company’s actual performance met investors’ expectations, making it closer to confirming a stable growth trend rather than a sudden, unexpected performance drop. The difference between the earnings disclosure figure and the market consensus is used as an important reference indicator for influencing subsequent stock price movements and investor sentiment.

In recent years, Samsung Biologics has been regarded as one of the main beneficiaries of the growing global demand for biopharmaceutical production. As the trend toward stronger R&D and production division among major global pharmaceutical and biotech companies continues to intensify, the role of contract manufacturing companies with large-scale production facilities and quality management capabilities has become increasingly prominent. This structural change not only supports quarterly performance, but also forms the foundation for long-term growth expectations.

This trend may likely continue in the future as global demand for contract manufacturing changes, the scale of new orders varies, and factory utilization rates fluctuate. However, the biopharmaceutical industry is highly sensitive to changes in customers’ production plans, exchange rates, and the regulatory environment; therefore, the direction of subsequent performance should be assessed with attention to both maintaining revenue growth and sustaining profitability.